Investors

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company employing epigenetics – a novel way to control gene expression – to overcome the problem of resistance seen with current oncology treatments. We are focused on the development and commercialization of our lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers.

NASDAQ: SNDX
$ 15.16 +0.27 (1.81%)
Day High: 15.62
Day Low:  14.79
Volume:    107,011
4:00 PM ET
09.30.16

Delayed ~20 min., by eSignal.

Press Releases


Events & Presentations